BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37026527)

  • 21. Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration.
    Janpipatkul K; Suksen K; Borwornpinyo S; Jearawiriyapaisarn N; Hongeng S; Piyachaturawat P; Chairoungdua A
    Cell Signal; 2014 Aug; 26(8):1668-79. PubMed ID: 24726839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALCAM is a Novel Cytoplasmic Membrane Protein in TNF-α Stimulated Invasive Cholangiocarcinoma Cells.
    Adisakwattana P; Suwandittakul N; Petmitr S; Wongkham S; Sangvanich P; Reamtong O
    Asian Pac J Cancer Prev; 2015; 16(9):3849-56. PubMed ID: 25987048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
    Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
    Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FBXO31 sensitizes cancer stem cells-like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma.
    Zhu Z; Zheng Y; He H; Yang L; Yang J; Li M; Dai W; Huang H
    Liver Int; 2022 Dec; 42(12):2871-2888. PubMed ID: 36269678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion.
    Wasuworawong K; Roytrakul S; Paemanee A; Jindapornprasert K; Komyod W
    Dis Markers; 2015; 2015():629367. PubMed ID: 25999659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PLAU contributes to the development of cholangiocarcinoma via activating NF-κB signaling pathway.
    Hu MD; Jia LH; Wang ML
    Cell Biol Int; 2023 Aug; 47(8):1381-1391. PubMed ID: 37067236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells.
    Oeurn K; Jusakul A; Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Kongpetch S
    In Vivo; 2023; 37(4):1628-1637. PubMed ID: 37369494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
    Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
    World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.
    Buranrat B; Senggunprai L; Prawan A; Kukongviriyapan V
    Life Sci; 2016 May; 153():41-9. PubMed ID: 27098189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Glucose Induced Upregulation of Cyclin a Associating with a Short Survival of Patients with Cholangiocarcinoma: A Potential Target for Treatment of Patients with Diabetes Mellitus.
    Saengboonmee C; Detarya M; Sangkhamanon S; Sawanyawisuth K; Seubwai W; Wongkham S
    Nutr Cancer; 2022; 74(5):1734-1744. PubMed ID: 34353198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
    Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
    Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
    Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
    PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
    Srijiwangsa P; Ponnikorn S; Na-Bangchang K
    BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
    Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
    Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus.
    Saengboonmee C; Sorin S; Sangkhamanon S; Chomphoo S; Indramanee S; Seubwai W; Thithuan K; Chiu CF; Okada S; Gingras MC; Wongkham S
    World J Gastroenterol; 2023 Jul; 29(28):4416-4432. PubMed ID: 37576707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
    Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
    Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.
    Treekitkarnmongkol W; Suthiphongchai T
    World J Gastroenterol; 2010 Aug; 16(32):4047-54. PubMed ID: 20731018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.